When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood of pharmaceutical companies.  Traditionally, they spend significant advertising dollars to create consumer awareness with the goal of influencing drug choices.  But when it comes to innovation for major chronic conditions like type 2 diabetes and heart disease, pharma companies need a lifeline.

The innovation pipeline is weak

There’s nothing really new coming down the pharma pipeline for diabetes or heart disease – I mean really NEW.  Sure, there are some combination therapies and long-acting injectables that have proven effective, but looking at the big picture, over the next 5-10 years, only 4% of drugs in the pipeline are for diabetes, and the likelihood of them getting to market is slimmer than slim.  The scenario is similar for heart disease.

So where’s the opportunity for innovation?  Who’s driving it?

There are plenty of opportunities for pharmaceutical and biotech companies, among other healthcare entities like payers and the government, to invest in finding solutions for managing chronic conditions and improving adherence instead of focusing on drug development.

Diabetes and heart disease are like the canary in the coal mine.  They are the signal of what needs to change for a lot of chronic conditions.  They are a signal of the end of the “just take a pill” era.  What’s driving this is the lack of innovation in the pipeline.

The future of innovation in diabetes and heart failure is not in new mechanisms of action.   The medication available for type 2 diabetes has been proven and the medicine is so cheap, it is almost free.  At this point, let’s focus on getting people to actually TAKE their medicine, vs. worrying about creating new medicines requiring big investments that have diminishing returns.

I can see a future where payers, even government themselves, play a larger role, especially with all the veterans and baby boomers on government health insurance. I can see a future where payers and government are saying to pharma, enough already with the me-too drugs and combination therapies.  Unless there is something that’s REALLY new, we are not interested.

Innovation will not be coming from the drugs themselves, but from other methods that strive to improve patient outcomes.  Clinical evidence and combination therapies will have minimal impact on improving treatment, but finding solutions to improve adherence is where the bigger opportunities are in these disease areas.

Digital’s role in medication adherence

Payers are going to be pushing for more than a pharmaceutical solution and will look to the tech challenge to improve medication adherence.  In fact, multiple clinical studies show that text messaging improves medication adherence in chronic disease, including a recent meta-analysis published in JAMA.  Typically, this type of research is initiated by hospitals and universities, not pharma companies.

Digital health solutions through mobile apps and devices are on the rise and becoming more accepted and embraced among consumers and physicians.  Especially in the diabetes space.  They empower patients to take control of their disease and help them stay in regular contact with their doctors.  Managing heart disease has been more of a tech challenge, most likely because the older population is not as comfortable using mobile devices.

Between heart failure and diabetes, over 40 million people are impacted.  If you don’t adhere to your basic medications and make some lifestyle adjustments, you are going to cost the system a lot of money. There will be more of a focus on helping people stick to a better lifestyle and take their medicine on a regular basis.  That alone will save inordinate amounts of money for the overall healthcare system and will drive a trend that puts the pharma companies in the back seat and the payer community in charge of treating patients with chronic diseases.

Not Your Grandparents’ Probability of Success Forecasts

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Healthiest States Index of The USA 2024

Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most precious assets for human beings. Good health provides better possibilities for us to overcome challenges in life and reap its benefits.  Do you...

FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development

FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval process that ensures patients have access to therapeutic agents proven to be safe and effective. The process relies upon a structured framework...

Finding the Needle in a Haystack with NLP

The problem with Big Data is that it is so Big!  This issue is especially true in the world of healthcare and drug development.  It is difficult to see across all the good clinical/scientific work going on around the world and understand exactly where we are headed...

China Reshaping the Clinical Trial Pipeline

Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China.  Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world....

Using Data to Optimize Clinical Trial Recruitment

The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials to assist with the placement, promotion, and sales of their products. If they are introducing a new mechanism of action (MOA) or modality...

Uncovering New Catalyst Events in the Pharmaceutical and Biotech Markets

The Challenges with Predicting Catalyst Events “Chasing headlines” for catalyst events in the biotech and pharmaceutical markets is a common frustration of investing in these spaces. Predicting these headlines in advance is a primary goal, along with mastering the...

New Developments in Alzheimer’s Treatment

OZMOSI’s predictions for where Alzheimer's treatment is headed. The Ravaging Effects of Alzheimer’s The devastation of living with an Alzheimer’s diagnosis is exponentially affecting more and more people. A 2019 study conducted by The Lancet estimated 57 million...

The Clinical Trial Powershift

Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and...